User profiles for PIET GEUSENS

Piet Geusens

MUMC and UH
Verified email at ping.be
Cited by 36771

[HTML][HTML] Effect of risedronate on the risk of hip fracture in elderly women

MR McClung, P Geusens, PD Miller… - New England journal …, 2001 - Mass Medical Soc
Background Risedronate increases bone mineral density in elderly women, but whether it
prevents hip fracture is not known. Methods We studied 5445 women 70 to 79 years old who …

Risk of new vertebral fracture in the year following a fracture

…, I Barton, SB Broy, A Licata, L Benhamou, P Geusens… - Jama, 2001 - jamanetwork.com
ContextVertebral fractures significantly increase lifetime risk of future fractures, but risk of
further vertebral fractures in the period immediately following a vertebral fracture has not been …

Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research

…, TA Einhorn, HK Genant, P Geusens… - Journal of bone and …, 2014 - academic.oup.com
Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures.
Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur …

Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo‐controlled trial (ASSERT)

…, B Dijkmans, P Geusens… - … : Official Journal of …, 2005 - Wiley Online Library
Objective The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to
nonsteroidal antiinflammatory drugs, corticosteroids, and disease‐modifying antirheumatic …

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

…, TA Einhorn, HK Genant, P Geusens… - Journal of Bone and …, 2010 - academic.oup.com
Reports linking long‐term use of bisphosphonates (BPs) with atypical fractures of the femur
led the leadership of the American Society for Bone and Mineral Research (ASBMR) to …

Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques

…, KBJM Cleutjens, PPM Geusens… - … , and vascular biology, 2001 - Am Heart Assoc
In the present study, we examined the expression of regulators of bone formation and
osteoclastogenesis in human atherosclerosis because accumulating evidence suggests that …

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy …

…, E Lespessailles, S Minisola, JJ Body, P Geusens… - The Lancet, 2018 - thelancet.com
Background No clinical trials have compared osteoporosis drugs with incident fractures as
the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in …

Epidemiology of fractures in the United Kingdom 1988–2012: variation with age, sex, geography, ethnicity and socioeconomic status

…, RJ Moon, JPW van den Bergh, P Geusens… - Bone, 2016 - Elsevier
Rates of fracture worldwide are changing. Using the Clinical Practice Research Datalink (CPRD),
age, and gender, geographical, ethnic and socioeconomic trends in fracture rates …

The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo …

…, J Han, A Berman, I Strusberg, P Geusens… - Arthritis & …, 2006 - Wiley Online Library
Objective To assess the risk of serious infections following 22 weeks of infliximab therapy,
and to further characterize the safety profile of infliximab in combination with background …

Clinical subsequent fractures cluster in time after first fractures

TACM van Geel, S van Helden, PP Geusens… - Annals of the …, 2009 - ard.bmj.com
Objectives: The risk of subsequent fractures is double the risk of having a first fracture. We
analysed whether this risk is constant or not over time. Methods: A population-based study in …